BRAF and colorectal cancer: Similarly, in a “real life” cohort of BRAF mutant metastatic colorectal cancers treated with targeted therapies as used in the BEACON trial in several Italian centers, the prevalence of MSI or Mismatch Repair deficiency was 15% [34].